Pharmacological intervention of blood flow disturbances in diabetic retinal disease - Retinal blood flow and diabetes

Phase 1

• Conditions: Diabetic retinal disease; MedDRA version: 9.1Level: LLTClassification code 10012661Term: Diabetic eye disease

• Registration Number: EUCTR2007-001697-84-DK
• Lead Sponsor: Department of Ophthalmology, Aarhus University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-06-12
• Last Update Posted: 3 May 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Diabetes type 1
Blood pressure < 135/85,
HbA1c < 9%
Moderate diabetic retinal disease
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Persons treated with antiglaucoma medicine
Persons with known eye disease, except diabetic retinal disease
Persons with cardio-vascular disease or blood pressure >140/90.
Pregnant women

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The pharmacological influence of latanoprost, diclofenac and dorzolamide on retinal vessel diameters;Secondary Objective: ;Primary end point(s): To estimate changes, due to pharmalogical intervention, in retinal vessels